Organon & Co. (OGN)
NYSE: OGN · Pharmaceutical Preparations · Jersey City, NJ
Our rating: Cautious
Cautious reaffirmed at $13.87, high conviction, November 6, 2026.
Breaks if: The Cautious call is wrong if Organon posts two consecutive quarterly revenue prints that are flat-to-growing year-over-year (0% or better) by the end of Q2 2027, while maintaining trailing-twelve-month FCF above $450M — evidence that the biosimilar and women's health segments are absorbing the patent losses faster than expected. A sustained recovery in the stock through $17.50 would signal the same re-rating and invalidate the call.
Key figures
| Market value | $3.6B |
|---|---|
| Revenue, last 12 months | $6.1B |
| Net income, last 12 months | $213M |
| Free cash flow, last 12 months | $675M |
| Price to earnings | 17.1× |
| Free cash flow yield | 18.5% |
| Dividend yield | 0.6% |
| Operating margin | n/a |
| Return on equity | 20.3% |
| Beta to the S&P 500 | 0.72 |
| Volatility, annualized | 55.3% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $1.6B | −1.7% | $0.60 | $326M |
| June 30, 2026 | $1.6B | −2.3% | $0.40 | $65M |
| March 31, 2026 | $1.5B | −3.5% | $0.55 | $188M |
| December 31, 2025 | $1.5B | −5.3% | $-0.78 | $96M |
| September 30, 2025 | $1.6B | 1.3% | $0.61 | $218M |
| June 30, 2025 | $1.6B | −0.8% | $0.56 | $181M |
| March 31, 2025 | $1.5B | −6.7% | $0.33 | $43M |
| December 31, 2024 | $1.6B | −0.4% | $0.41 | $335M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $1.46B: Claude 82%, Gemini 90%, Mistral 85%
- Diluted earnings per share are above zero: Claude 78%, Gemini 95%, Mistral 92%
- Free cash flow for the quarter is at least $0.10B: Claude 60%, Gemini 75%, Mistral 70%
13 ledger entries and 17 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.